Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AUPH
- CUSIP: N/A
- Web: www.auriniapharma.com
Capitalization:- Market Cap: $507.96 million
- Outstanding Shares: 83,272,000
Average Prices:- 50 Day Moving Avg: $6.70
- 200 Day Moving Avg: $5.22
- 52 Week Range: $1.74 - $10.54
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.98
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $147,000.00
- Price / Sales: 3,455.50
- Book Value: $2.10 per share
- Price / Book: 2.90
Profitability:- EBIDTA: ($26,510,000.00)
- Net Margins: -48,278.23%
- Return on Equity: -50.53%
- Return on Assets: -36.88%
Debt:- Current Ratio: 24.60%
- Quick Ratio: 24.61%
Misc:- Average Volume: 4.63 million shs.
- Beta: 2.62
- Short Ratio: 3.34
Frequently Asked Questions for Aurinia Pharmaceuticals (NASDAQ:AUPH)
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.08. The firm earned $0.03 million during the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 48,278.23% and a negative return on equity of 50.53%. View Aurinia Pharmaceuticals' Earnings History.
Where is Aurinia Pharmaceuticals' stock going? Where will Aurinia Pharmaceuticals' stock price be in 2017?
7 brokers have issued 1-year price objectives for Aurinia Pharmaceuticals' shares. Their forecasts range from $8.00 to $14.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $10.67 in the next twelve months. View Analyst Ratings for Aurinia Pharmaceuticals.
What are analysts saying about Aurinia Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
- 1. FBR & Co analysts commented, "We increase our price target 22% from $9 to $11, as we think that with a balance sheet bolstered by a public offering that we estimate raised up to $161M in net proceeds, AUPH is now in a strong position to independently advance voclosporin (VCS), its investigational therapy for patients with active lupus nephritis (LN), into Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by major pharmaceutical companies (Big Pharma) hungry for the next multi-billiondollar drug (FBR projects VCS could achieve >$2B in annual peak sales), we look for AUPH to receive an acquisition bid from a Big Pharma company in the next six to nine months, with an initial bid of $10 per share reasonable. We think AUPH is more likely to look to sign a partnership agreement; therefore, we look for a deal worth $500M to $700M in up-front and milestone payments to AUPH. We reiterate our Outperform rating." (3/22/2017)
- 2. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (3/20/2017)
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Synergy Pharmaceuticals (SGYP), Omeros Corporation (OMER), Clinigen Group PLC (CLIN), Forward Pharma A/S (FWP), Amarin Corporation PLC (AMRN), Xencor (XNCR), Insys Therapeutics (INSY), Acorda Therapeutics (ACOR), Five Prime Therapeutics (FPRX), Epizyme (EPZM), Ascendis Pharma A/S (ASND), ZIOPHARM Oncology (ZIOP), Coherus BioSciences (CHRS), Revance Therapeutics (RVNC), Achaogen (AKAO), Aduro Biotech (ADRO), NeuroDerm (NDRM) and Keryx Biopharmaceuticals (KERX).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer
- Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
- Michael R. Martin, Chief Operating Officer
- Neil Solomons M.D., Chief Marketing Officer
- Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
- Robert B. Huizinga, Vice President - Clinical Affairs
- Lawrence D. Mandt, Vice President - Regulatory and Quality
- George M. Milne Jr., Ph.D., Director
- Lorin Jeffry Randall, Director
- Benjamin Rovinski Ph.D., Independent Director
Who owns Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (0.00%), NEA Management Company LLC (0.00%), Morgan Stanley (0.00%), UBS Oconnor LLC (0.48%), AWM Investment Company Inc. (0.00%) and Nicholas Investment Partners LP (0.47%). View Institutional Ownership Trends for Aurinia Pharmaceuticals.
Who bought Aurinia Pharmaceuticals stock? Who is buying Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, NEA Management Company LLC, Morgan Stanley, UBS Oconnor LLC, AWM Investment Company Inc., Nicholas Investment Partners LP, Monashee Investment Management LLC and OTA Financial Group L.P.. View Insider Buying and Selling for Aurinia Pharmaceuticals.
How do I buy Aurinia Pharmaceuticals stock?
Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $6.10.
MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)Earnings History by Quarter for Aurinia Pharmaceuticals (NASDAQ AUPH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/15/2017 | 3/31/2017 | ($0.12) | ($0.20) | $0.05 million | $0.03 million | View | N/A |  |
| 3/9/2017 | Q4 | ($0.12) | ($0.22) | $0.06 million | $0.03 million | View | N/A | |
| 5/11/2016 | Q1 | ($0.14) | ($0.13) | $0.10 million | $0.06 million | View | N/A | |
| 3/18/2016 | Q4 | ($0.16) | ($0.16) | $0.09 million | $0.06 million | View | N/A | |
| 3/30/2015 | Q4 2014 | ($0.11) | ($0.15) | $0.10 million | $0.07 million | View | N/A | |
| 11/12/2014 | Q3 14 | | ($0.08) | | $0.07 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)2017 EPS Consensus Estimate: ($0.52)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.13) | ($0.10) | ($0.12) |
| Q2 2017 | 2 | ($0.13) | ($0.11) | ($0.12) |
| Q3 2017 | 2 | ($0.14) | ($0.12) | ($0.13) |
| Q4 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
(Data provided by Zacks Investment Research)
Dividend History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Latest Headlines for Aurinia Pharmaceuticals (NASDAQ:AUPH)
| Source: |
|
| Date | Headline |
|---|
 | Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 8:02 AM |
 | Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC
finance.yahoo.com - June 21 at 4:40 PM |
| $50,000.00 in Sales Expected for Aurinia Pharmaceuticals Inc (AUPH) This Quarter
www.americanbankingnews.com - June 21 at 11:48 AM |
 | Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't? - Nasdaq
www.nasdaq.com - June 20 at 9:25 PM |
 | Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
www.zacks.com - June 20 at 4:22 PM |
| Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
finance.yahoo.com - June 20 at 4:22 PM |
| Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - June 19 at 7:48 AM |
 | Ongoing Aurinia Pharmaceuticals Study Results Boost Shares Higher - Benzinga
www.benzinga.com - June 16 at 9:28 PM |
| Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017
finance.yahoo.com - June 16 at 4:25 PM |
| Aurinia Pharma Rises Following Updated Mid-Stage Results
finance.yahoo.com - June 16 at 4:25 PM |
| Ongoing Aurinia Pharmaceuticals Study Results Boost Shares Higher
feeds.benzinga.com - June 16 at 9:22 AM |
| Aurinia Pharmaceuticals Inc (AUPH) Expected to Post FY2017 Earnings of ($1.15) Per Share
www.americanbankingnews.com - June 9 at 8:58 AM |
 | Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma
www.prnewswire.com - June 8 at 8:24 AM |
 | Aurinia Pharmaceuticals (AUPH) Presents Additional Data from Phase Iib Aura-Lv Study - StreetInsider.com
www.streetinsider.com - June 6 at 3:51 PM |
| Aurinia Pharmaceuticals (AUPH) Presents Additional Data from Phase IIB AURA-LV Study at ERA-EDTA Congress - StreetInsider.com
www.streetinsider.com - June 5 at 1:03 PM |
| Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks
finance.yahoo.com - June 5 at 1:03 PM |
| Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 5:02 PM |
| Aurinia Pharmaceuticals (AUPH) To Participate In Late Breaking Oral Presentations At 2 Upcoming Scientific ... - StreetInsider.com
www.streetinsider.com - May 31 at 3:44 PM |
| Aurinia Pharmaceuticals (AUPH) To Participate In Late Breaking Oral Presentations At 2 Upcoming Scientific Conferences
www.streetinsider.com - May 31 at 10:50 AM |
| Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 8:00 AM |
| Leerink Swann Weighs in on Aurinia Pharmaceuticals Inc's Q2 2017 Earnings (AUPH)
www.americanbankingnews.com - May 18 at 8:21 AM |
| Aurinia Pharmaceuticals Inc (AUPH) Given New $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 18 at 8:10 AM |
| Aurinia Pharmaceuticals (AUPH) Doses First Patient in AURORA Phase 3 Trial of Voclosporin in LN
www.streetinsider.com - May 17 at 8:46 PM |
| Aurinia Pharmaceuticals Inc (AUPH) Posts Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - May 16 at 3:48 PM |
| Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics
finance.yahoo.com - May 16 at 12:27 PM |
| Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
finance.yahoo.com - May 15 at 4:13 PM |
| Aurinia reports 1Q loss
finance.yahoo.com - May 15 at 4:13 PM |
| Aurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : May 11, 2017
finance.yahoo.com - May 11 at 9:10 PM |
| Aurinia Pharmaceuticals Inc (AUPH) Short Interest Up 22.2% in April
www.americanbankingnews.com - May 11 at 8:36 AM |
| Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season? - Nasdaq
www.nasdaq.com - May 10 at 8:54 PM |
| Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
www.zacks.com - May 9 at 9:07 AM |
| Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
finance.yahoo.com - May 9 at 9:07 AM |
| Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : May 9, 2017
finance.yahoo.com - May 9 at 9:07 AM |
 | Aurinia Pharmaceuticals Is A Top Pick For H2 2017 - Seeking Alpha
seekingalpha.com - May 2 at 3:45 PM |
| Aurinia Pharmaceuticals (AUPH) Receiving Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 12:20 PM |
| 3 Best Biotech Stocks During Trump's First 100 Days
finance.yahoo.com - May 1 at 3:45 PM |
| Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - May 1 at 11:03 AM |
| Aurinia Pharmaceuticals (AUPH) Receives Daily Media Impact Rating of 0.20
www.americanbankingnews.com - April 29 at 9:58 AM |
| Aurinia Pharmaceuticals (AUPH) Earning Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 26 at 4:54 PM |
| Aurinia to Present at Bloom Burton & Co. Healthcare Conference
finance.yahoo.com - April 26 at 10:19 AM |
| Aurinia Pharmaceuticals (AUPH) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 23 at 10:17 AM |
| Aurinia Pharmaceuticals' (AUPH) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 22 at 6:32 PM |
| Aurinia Pharmaceuticals (AUPH) Presents At National Kidney Foundation 2017 (48-Week Data from the AURA-LV Study) - Slideshow
seekingalpha.com - April 21 at 8:50 PM |
| Aurinia Pharmaceuticals (AUPH) Earning Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 20 at 8:21 AM |
| Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock Options
finance.yahoo.com - April 19 at 10:07 AM |
| Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome
finance.yahoo.com - April 18 at 10:28 AM |
| Aurinia Pharmaceuticals (AUPH) Given Media Sentiment Rating of 0.23
www.americanbankingnews.com - April 17 at 2:06 PM |
| Aurinia Pharmaceuticals' (AUPH) "Outperform" Rating Reaffirmed at FBR & Co
www.americanbankingnews.com - April 17 at 8:44 AM |
| Aurinia Pharmaceuticals (AUPH) Getting Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 14 at 5:21 PM |
| Aurinia Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($0.55) Per Share (AUPH)
www.americanbankingnews.com - April 14 at 12:20 PM |
Aurinia Pharmaceuticals (AUPH) Chart for Tuesday, June, 27, 2017
